{
    "clinical_study": {
        "@rank": "55201", 
        "arm_group": [
            {
                "arm_group_label": "Standard regimen", 
                "description": "Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab"
            }, 
            {
                "arm_group_label": "Rheumatoid arthritis regimen", 
                "description": "Patients received  the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this large French multicentric retrospective study was to compare the efficacy\n      and safety of two (the standard and the Rheumatoid arthritis) rituximab regimens in adult's\n      immune thrombocytopenia ."
        }, 
        "brief_title": "Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Primary Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "Every adult (age \u2265 18 years) seen in one of the 3 participating centre (dijon, Marseille,\n      Mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary ITP according\n      to the American Society Hematology guidelines who received RTX regardless the regimen could\n      be included."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Primary ITP\n\n          -  Age > 18 years\n\n        Exclusion Criteria:\n\n          -  Secondary ITP\n\n          -  Age < 18 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary ITP patients treated with standard or RA regimen were retrospectively included in\n        the observationnal study."
            }
        }, 
        "enrollment": {
            "#text": "107", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01727232", 
            "org_study_id": "Mondor-Rituxcompare"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ITP", 
            "Rituximab", 
            "Efficacy", 
            "Anti-CD20", 
            "Regimen"
        ], 
        "lastchanged_date": "November 12, 2012", 
        "number_of_groups": "2", 
        "official_title": "Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: National Consultative Ethics Committee for Health and Life Sciences", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "A complete response (CR) was defined as a platelet count >100 x 109/l and a response (R): by a platelet count >30 x 109/l with a least a doubling of the baseline value without any rescue intervention within 8 weeks before assessment, and no response (NR) was defined as a platelet count lower than 30 x 109/", 
            "measure": "The primary end point of the study was to assess the response rate to treatment 1 year after the first rituximab infusion.", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01727232"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Henri Mondor University Hospital", 
            "investigator_full_name": "Dr Mah\u00e9vas Matthieu, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The response rate 3months, and at the last follow-up after the first rituximab infusion. Variable associated with RTX response.", 
            "safety_issue": "Yes", 
            "time_frame": "3 months, one year, last follow-up"
        }, 
        "source": "Henri Mondor University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Henri Mondor University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2007", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}